50 related articles for article (PubMed ID: 8819248)
1. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus.
Davì G; Belvedere M; Vigneri S; Catalano I; Giammarresi C; Roccaforte S; Consoli A; Mezzetti A
Thromb Haemost; 1996 Jul; 76(1):34-7. PubMed ID: 8819248
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
3. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
6. Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
Davì G; Catalano I; Averna M; Notarbartolo A; Strano A; Ciabattoni G; Patrono C
N Engl J Med; 1990 Jun; 322(25):1769-74. PubMed ID: 2345567
[TBL] [Abstract][Full Text] [Related]
7. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
[TBL] [Abstract][Full Text] [Related]
8. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
[TBL] [Abstract][Full Text] [Related]
9. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration.
Davì G; Chiarelli F; Santilli F; Pomilio M; Vigneri S; Falco A; Basili S; Ciabattoni G; Patrono C
Circulation; 2003 Jul; 107(25):3199-203. PubMed ID: 12810609
[TBL] [Abstract][Full Text] [Related]
10. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
12. [Diabetes, coagulation and vascular events].
Nenci GG; Paliani U
Recenti Prog Med; 2000 Feb; 91(2):86-90. PubMed ID: 10748654
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
Herlihy OM; Barrow BA; Grant PJ; Levy JC
Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
[TBL] [Abstract][Full Text] [Related]
16. The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients.
Ogawa S; Takeuchi K; Sugimura K; Sato C; Fukuda M; Lee R; Ito S; Sato T
Clin Exp Pharmacol Physiol; 1999; 26(5-6):461-4. PubMed ID: 10386239
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
18. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
19. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
Savage S; Estacio RO; Jeffers B; Schrier RW
Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
[TBL] [Abstract][Full Text] [Related]
20. [Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions].
Galajda P; Sutarík L; Vladár L; Stasko J; Kubisz P; Mokán M
Vnitr Lek; 1998 Feb; 44(2):111-4. PubMed ID: 9820087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
